Rocket Pharmaceuticals (RCKT) Long-Term Investments (2018 - 2023)
Rocket Pharmaceuticals' (RCKT) quarterly Long-Term Investments came in at $34.3 million in Q4 2023, down 20.7% year-on-year from $43.3 million in Q4 2022, and up 18.52% quarter-over-quarter from $29.0 million in Q1 2023.
Rocket Pharmaceuticals (RCKT) Long-Term Investments (2018 - 2023) Analysis & Trends
Rocket Pharmaceuticals has disclosed Long-Term Investments across 3 years of filings, most recently posting $34.3 million for Q4 2023.
- Long-Term Investments for Q4 2023 came in at $34.3 million, down 20.7% year-over-year; the trailing twelve-month figure through Dec 2023 was $34.3 million (down 20.7% YoY), and the FY2023 annual result was $34.3 million, down 20.7% from the prior year.
- Long-Term Investments came in at $34.3 million for Q4 2023 at Rocket Pharmaceuticals, up from $29.0 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $43.3 million in Q4 2022 to a low of $29.0 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Rocket Pharmaceuticals | 296.03 Mn | 296.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 34.32 Mn |
| Mar 31, 2023 | 28.96 Mn |
| Dec 31, 2022 | 43.28 Mn |
| Dec 31, 2018 | 7.40 Mn |
| Sep 30, 2018 | 32.00 Mn |
| Jun 30, 2018 | 39.36 Mn |